RecruitingEarly Phase 1NCT05093335
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Studying Erdheim-Chester disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Anton Nosov, MD, M.DMemorial Sloan Kettering Cancer Center
- Intervention
- [68Ga]-Pentixafor(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (1)
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05093335 on ClinicalTrials.govOther trials for Erdheim-Chester disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07454343ECD-Score: a Study on Erdheim-Chester DiseaseMeyer Children's Hospital IRCCS
- RECRUITINGNCT05915208Histiocytic Disorder Follow-up StudyUniversity of Alabama at Birmingham
- RECRUITINGPHASE2NCT04079179Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersCarl Allen
- RECRUITINGNCT03990428Supportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic DiseasesMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT03329274Registry for Patients With Erdheim-Chester Disease and Other HistiocytosesMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT02523040Lenalidomide for Adult Histiocyte DisordersDana-Farber Cancer Institute
- RECRUITINGNCT02285582International Rare Histiocytic Disorders Registry (IRHDR)The Hospital for Sick Children